Review
Copyright ©The Author(s) 2019.
World J Hepatol. May 27, 2019; 11(5): 421-441
Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.421
Table 1 Clinical efficacy of direct acting antiviral in major empirical studies in China
Study InformationStudy regimenSVR12Ref.
Pivotal phase 3; TN patients; GT1bDCV + ASVNon-cirrhotic: 92%[45]
Cirrhotic: 94%
Pivotal phase 3b; TN and TE patients; GT1, 2, 3, 6SOF + RBV ± PEG-IFNNon-cirrhotic GT1/2/3/6: 96%/93%/97%/100%[49]
Cirrhotic GT1/2/3/6: 84%/88%/88%/50%
(GT6 with cirrhosis: n = 2)
Pivotal phase 3b; TN and TE patients; GT1bLDV/SOF100%[46]
Pivotal phase 3; TN and TE patients; GT1b, 2, 3, 6SOF/VELGT1b/2/3/6: 100%/100%/83%/100% (Subgroup SVR12: GT3a: 91%; GT3b non-cirrhotic/cirrhotic: 96%/50%)[50]
Pivotal phase 3; TN patients; GT1, 6EBR/GZRGT1/6: 97%/80% (GT1: 140/146 patients were GT1b; GT6: n = 5)[48]
Pivotal phase 3; TN and TE patients; GT1bO/P/r + D99%–100%[47]
Prospective cohort; TE; GT1bSOF + DCV100% (SVR24)[53]
LDV/SOF100% (SVR24)
PEG-IFN + RBV28% (SVR24)
Real-world study; TN and TE HCV patients with DCCSOF-containing regimens90%; with significant improvement in hepatic function among SVR patients[54]
Table 2 Model predicted long-term clinical outcomes of using direct acting antivirals in China
Study InformationRegimens comparedPredicted reduction in liver sequelae relative to PR therapy
DCCHCCLiver transplantLiver-related death
Simulating 10000 Chinese CHC patients over a lifetime horizon;GLE/PIB[57]-95%-90%-95%-92%
SOF/VEL[56,57]-96%-91%-96%-93%
DCV + ASV[56]-51%-48%-51%-49%
O/P/r + D[56]-59%-55%-59%-57%
EBR/GZR[56]-59%-55%-59%-57%
GT1b, 2, 3, 6